Associated Papers
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
Estupiñán HY et al.
Leukemia, 2021
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
Smith CIE et al.
Frontiers in Immunology, 2021
Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.
Kozaki R et al.
Cancers, 2018
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
Sharma S et al.
Oncotarget, 2016
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Davis RE et al.
Nature, 2010
Naturally occurring Bruton's tyrosine kinase mutations have no dominant negative effect in an X-linked agammaglobulinaemia cellular model.
Pérez de Diego R et al.
Clinical and Experimental Immunology, 2008
[Genetic diagnosis of patients with primary agammaglobulinemia treated at third level peruvian centers].
Matos-Benavides E et al.
Revista Peruana De Medicina Experimental Y Salud Publica, 0
Select a paper to view details